Capsule Summary Slidesets

Share

Program Content

Activities

  • Cevostamab in RRMM
    Phase I Study of Cevostamab in Patients With Heavily Pretreated R/R MM: Dosing Schedule, Updated Safety and Efficacy Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • MonumenTAL-1: Talquetamab in R/R MM
    Phase I MonumenTAL-1: GPCR5D x CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • REGN5458 in R/R MM
    Phase I/II Study of BCMA x CD3 Bispecific Antibody REGN5458 in R/R MM: Updated Safety and Efficacy Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • IBER + DEX in RRMM
    Dose-Expansion Results From Phase Ib/IIa CC-220-MM-001 Trial: Iberdomide + Dexamethasone in Relapsed/Refractory MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2021

    Expires: December 11, 2022

  • Belantamab + Len/Dex in NDMM
    Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • DREAMM-9
    Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • GMMG-HD7
    GMMG-HD7: Phase III Trial of Isatuximab + VRd vs VRD Alone as Induction Therapy for Newly Diagnosed, ASCT-Eligible Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • GEM2014MAIN: Ixa + LenDex
    Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • CARTITUDE-1: 2-Yr Update
    CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel in Patients With R/R MM: 2-Yr Update
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • GRIFFIN Update: Dara-R Maintenance
    GRIFFIN 2-Yr Maintenance Phase Update: Dara + VRd With Dara-R Maintenance vs VRd With R Maintenance for ASCT-Eligible Patients With Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2021

    Expires: December 21, 2022

  • Venetoclax/Dara/Dex in R/R MM
    Preliminary Phase I/II Results of Venetoclax/Dara/Dex vs Bortezomib/Dara/Dex in t(11;14) Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • MCARH109 CAR T-Cell Tx in R/R MM
    MCARH109, a GPCRC5D-Targeted CAR T-Cell Therapy, in Relapsed/Refractory MM: A Phase I First-in-Class Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • Final BELLINI Analysis: Venetoclax + Vd
    Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • MajesTEC-1:  Teclistamab in R/R MM
    Updated Results From Phase I/II MajesTEC-1 Study: Teclistamab, a BCMA x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • ABBV-383 in R/R MM
    BCMA x CD3 Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma: Update of a Phase I First-in-Human Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation